Smart Accumulating Dual-Targeting Lipid Envelopes Equipping Oncolytic Adenovirus for Enhancing Cancer Gene Therapeutic Efficacy
Source abstract
Abstract
Systemic delivery of oncolytic adenovirus (oAd) for cancer gene therapy must overcome several limitations such as rapid clearance from the blood, nonspecific accumulation in the liver, and insufficient delivery to the tumor tissues. In the present report, a tumor microenvironment-triggered artificial lipid envelope composed of a pH-responsive sulfamethazine-based polymer (PUSSM)-conjugated phospholipid (DOPE-HZ-PUSSM) and another lipid decorated with epidermal growth factor receptor (EGFR) targeting peptide (GE11) (GE11-DOPE) was utilized to encapsulate replication-incompetent Ad (dAd) or oAd coexpressing short-hairpin RNA (shRNA) against Wnt5 (shWnt5) and decorin (dAd/LP-GE-PS or oAd/LP-GE-PS, respectively). In vitro studies demonstrated that dAd/LP-GE-PS transduced breast cancer cells in a pH-responsive and EGFR-specific manner, showing a higher level of transduction than naked Ad under a mildly acidic pH of 6.0 in EGFR-positive cell lines. In vivo biodistribution analyses revealed that systemic administration of oAd/LP-GE-PS leads to a significantly higher level of intratumoral virion accumulation compared to naked oAd, oAd encapsulated in a liposome without PUSSM or EGFR targeting peptide moiety (oAd/LP), or oAd encapsulated in a liposome with EGFR targeting peptide alone (oAd/LP-GE) in an EGFR overexpressing MDA-MB-468 breast tumor xenograft model, showing that both pH sensitivity and EGFR targeting ability were integral to effective systemic delivery of oAd. Further, systemic administration of all liposomal oAd formulations (oAd/LP, oAd/LP-GE, and oAd/LP-GE-PS) showed significantly attenuated hepatic accumulation of the virus compared to naked oAd. Collectively, our findings demonstrated that pH-sensitive and EGFR-targeted liposomal systemic delivery of oAd can be a promising strategy to address the conventional limitations of oAd to effectively treat EGFR-positive cancer in a safe manner.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Virus-based gene therapy research · RNA Interference and Gene Delivery · Cancer Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Bioengineering, College of Engineering, Hanyang University, Seoul 04763, South Korea
GeneMedicine CO., Ltd., Seoul 04763, South Korea
Institute of Nano Science and Technology (INST), Hanyang University, Seoul 04763, South Korea
Hanyang Institute of Bioscience and Biotechnology (HY-IBB), Hanyang University, Seoul 04763, South Korea
Funding
Ministry of Science and ICT, South Korea · National Research Foundation of Korea · Hanyang University
References (94)
Show source-provided references
1. 10.3322/caac.2176310.3322/caac.21763 ↗
2. 10.1016/j.omto.2019.10.00710.1016/j.omto.2019.10.007 ↗
3. 10.1002/ijc.2099510.1002/ijc.20995 ↗
4. 10.1089/hum.2013.23510.1089/hum.2013.235 ↗
5. 10.3389/fimmu.2022.82687610.3389/fimmu.2022.826876 ↗
6. Hecht J. R. · Clin. Cancer Res. · 2003 · 9 · 555
7. DeWeese T. L. · Cancer Res. · 2001 · 61 · 7464
8. 10.1038/ncponc073610.1038/ncponc0736 ↗
9. 10.3390/biomedicines503004610.3390/biomedicines5030046 ↗
10. 10.1089/hum.2009.02810.1089/hum.2009.028 ↗
11. 10.1007/978-1-62703-679-5_910.1007/978-1-62703-679-5_9 ↗
12. 10.1371/journal.pone.000891610.1371/journal.pone.0008916 ↗
13. 10.18632/oncotarget.2081010.18632/oncotarget.20810 ↗
14. 10.3390/cancers1308186310.3390/cancers13081863 ↗
15. 10.3390/v210229010.3390/v2102290 ↗
16. 10.1038/s41392-023-01407-610.1038/s41392-023-01407-6 ↗
17. 10.1016/j.nantod.2022.10167110.1016/j.nantod.2022.101671 ↗
18. 10.1158/0008-5472.CAN-18-390010.1158/0008-5472.CAN-18-3900 ↗
19. 10.3390/cells1005097810.3390/cells10050978 ↗
20. 10.1007/s12274-021-4031-610.1007/s12274-021-4031-6 ↗
21. 10.1016/j.nano.2021.10250610.1016/j.nano.2021.102506 ↗
22. 10.1016/j.addr.2013.12.00810.1016/j.addr.2013.12.008 ↗
23. 10.1016/j.msec.2017.02.01210.1016/j.msec.2017.02.012 ↗
24. 10.1021/acsnano.1c0499610.1021/acsnano.1c04996 ↗
25. Lasic D. D. · Curr. Opin Mol. Ther · 1999 · 1 · 177
26. 10.1002/nbm.101110.1002/nbm.1011 ↗
27. 10.1089/1043034995001705910.1089/10430349950017059 ↗
28. 10.1016/S1368-8375(03)00047-210.1016/S1368-8375(03)00047-2 ↗
29. 10.1089/hum.1998.9.17-249310.1089/hum.1998.9.17-2493 ↗
30. 10.1038/sj.cgt.770023710.1038/sj.cgt.7700237 ↗
31. 10.1128/JVI.77.8.4858-4866.200310.1128/JVI.77.8.4858-4866.2003 ↗
32. 10.1248/bpb.23.79110.1248/bpb.23.791 ↗
33. 10.1016/j.biomaterials.2012.08.03110.1016/j.biomaterials.2012.08.031 ↗
34. 10.1007/s11307-018-1238-310.1007/s11307-018-1238-3 ↗
35. 10.1021/acsami.7b0286310.1021/acsami.7b02863 ↗
36. 10.1016/j.addr.2008.08.00510.1016/j.addr.2008.08.005 ↗
37. 10.1016/j.jconrel.2010.08.02710.1016/j.jconrel.2010.08.027 ↗
38. 10.1016/j.drup.2005.10.00210.1016/j.drup.2005.10.002 ↗
39. 10.1016/j.jconrel.2011.10.01310.1016/j.jconrel.2011.10.013 ↗
40. 10.1016/j.addr.2009.03.00110.1016/j.addr.2009.03.001 ↗
41. 10.1111/j.1742-4658.2009.07448.x10.1111/j.1742-4658.2009.07448.x ↗
42. 10.1096/fj.05-4058com10.1096/fj.05-4058com ↗
43. 10.3389/fonc.2023.122302510.3389/fonc.2023.1223025 ↗
44. 10.1016/j.ijpharm.2018.06.02810.1016/j.ijpharm.2018.06.028 ↗
45. 10.1016/j.ijpharm.2020.11968010.1016/j.ijpharm.2020.119680 ↗
46. 10.1016/j.colsurfb.2018.01.01810.1016/j.colsurfb.2018.01.018 ↗
47. 10.1021/ab500119410.1021/ab5001194 ↗
48. 10.3389/fchem.2022.90564510.3389/fchem.2022.905645 ↗
49. 10.3390/polym1405093610.3390/polym14050936 ↗
50. 10.1016/j.biomaterials.2014.09.00610.1016/j.biomaterials.2014.09.006 ↗
51. 10.1021/nn402201w10.1021/nn402201w ↗
52. 10.1016/j.carbpol.2019.11528110.1016/j.carbpol.2019.115281 ↗
53. 10.1063/1.508573610.1063/1.5085736 ↗
54. 10.1021/bi00438a03110.1021/bi00438a031 ↗
55. 10.1016/S0021-9797(02)00082-610.1016/S0021-9797(02)00082-6 ↗
56. 10.1021/acs.biomac.8b0081910.1021/acs.biomac.8b00819 ↗
57. 10.1073/pnas.85.18.694910.1073/pnas.85.18.6949 ↗
58. 10.1016/j.fitote.2012.02.00410.1016/j.fitote.2012.02.004 ↗
59. 10.1038/s41598-022-23013-210.1038/s41598-022-23013-2 ↗
60. Narenji M. · Iran J. Pharm. Res. · 2017 · 16 · 423
61. 10.1007/s00432-003-0521-z10.1007/s00432-003-0521-z ↗
62. 10.1016/j.cbi.2021.10973510.1016/j.cbi.2021.109735 ↗
63. 10.1007/s10549-012-2289-910.1007/s10549-012-2289-9 ↗
64. 10.1016/j.jcis.2022.12.01910.1016/j.jcis.2022.12.019 ↗
65. 10.3892/or.2014.333010.3892/or.2014.3330 ↗
66. 10.3390/cancers1206140310.3390/cancers12061403 ↗
67. 10.1038/cgt.2012.7910.1038/cgt.2012.79 ↗
68. 10.37349/etat.2020.0000510.37349/etat.2020.00005 ↗
69. 10.1016/j.apsb.2021.01.01210.1016/j.apsb.2021.01.012 ↗
70. 10.1158/1078-0432.CCR-04-022010.1158/1078-0432.CCR-04-0220 ↗
71. 10.1186/s12964-019-0419-210.1186/s12964-019-0419-2 ↗
72. 10.1200/JCO.2009.25.982010.1200/JCO.2009.25.9820 ↗
73. 10.1186/1476-4598-9-12210.1186/1476-4598-9-122 ↗
74. 10.7150/thno.2147710.7150/thno.21477 ↗
75. 10.1016/j.actbio.2019.06.05910.1016/j.actbio.2019.06.059 ↗
76. 10.1016/j.biomaterials.2014.11.05310.1016/j.biomaterials.2014.11.053 ↗
77. 10.1039/C8NA00190A10.1039/C8NA00190A ↗
78. 10.1016/j.jcyt.2021.07.01310.1016/j.jcyt.2021.07.013 ↗
79. 10.3390/biomedicines1007169710.3390/biomedicines10071697 ↗
80. 10.3389/fimmu.2022.95341010.3389/fimmu.2022.953410 ↗
81. 10.1016/j.omtm.2020.01.00110.1016/j.omtm.2020.01.001 ↗
82. 10.1038/s41392-023-01683-210.1038/s41392-023-01683-2 ↗
83. 10.1038/ncomms1475410.1038/ncomms14754 ↗
84. 10.3389/fcimb.2019.0020710.3389/fcimb.2019.00207 ↗
85. 10.1038/bjc.2015.10110.1038/bjc.2015.101 ↗
86. 10.1089/hum.2015.09810.1089/hum.2015.098 ↗
87. 10.1089/hum.2011.00310.1089/hum.2011.003 ↗
88. 10.1016/j.jconrel.2007.08.00210.1016/j.jconrel.2007.08.002 ↗
89. 10.1089/10430340376921163710.1089/104303403769211637 ↗
90. 10.1038/s41598-018-19300-610.1038/s41598-018-19300-6 ↗
91. 10.1039/C6TB01690A10.1039/C6TB01690A ↗
92. 10.1002/pol.1984.17022020710.1002/pol.1984.170220207 ↗
93. 10.1016/j.biomaterials.2010.10.03110.1016/j.biomaterials.2010.10.031 ↗
94. 10.1016/j.biomaterials.2017.08.03510.1016/j.biomaterials.2017.08.035 ↗